Patient‐reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial

OBJECTIVES: The ECOG‐ACRIN Cancer Research Group trial E2511 recently demonstrated a potential benefit for the addition of veliparib to cisplatin‐etoposide (CE) in patients with extensive stage small cell lung cancer (ES‐SCLC) in a phase II randomized controlled trial. Secondary trial endpoints incl...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Med
Autors principals: Steffen McLouth, Laurie E., Zhao, Fengmin, Owonikoko, Taofeek K., Feliciano, Josephine L., Mohindra, Nisha A., Dahlberg, Suzanne E., Wade, James L., Srkalovic, Gordan, Lash, Bradley W., Leach, Joseph W., Leal, Ticiana A., Aggarwal, Charu, Cella, David, Ramalingam, Suresh S., Wagner, Lynne I.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Clinical Cancer Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7571824/
https://ncbi.nlm.nih.gov/pubmed/32860331
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3416
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars